Baxter Renews Support of NHF Fellowship Program to Promote Excellence in
Hemophilia Care
DEERFIELD, Ill. and NEW YORK, Sept. 29 /PRNewswire-FirstCall/ -- The
National Hemophilia Foundation (NHF) has announced the award of two (2)
two- year fellowships for 2006/2007 through the NHF Clinical Fellowship
Program in Bleeding Disorders Research, sponsored by Baxter Healthcare
Corporation. The program recognizes the need to support new future leaders
specializing in coagulation disorders. It was developed to help educate and
train physicians to provide comprehensive care for people with bleeding or
clotting disorders, such as hemophilia, von Willebrand disease and
thrombophilia.
"NHF is proud to support the training of the next generation of
physicians who will treat bleeding and clotting disorders," said Alan
Kinniburgh, Ph.D., Chief Executive Officer of the National Hemophilia
Foundation. "This generous sponsorship is an exceptional way for Baxter
Healthcare to help sustain high quality care for individuals with bleeding
and clotting disorders."
In 2005, Baxter expanded its total financial support for the fellowship
program to more than $3.6 million to provide support for two new
fellowships each year through 2008.
"These fellowships will have a profound impact over the next decade.
Four graduates of the program have already received assistant professorship
appointments at key teaching and research institutions focusing on
coagulation," said W. Keith Hoots, M.D., Director of the Gulf States
Hemophilia & Thrombophilia Treatment and Chair of NHF's Medical and
Scientific Advisory Council (MASAC). "The individuals coming out of this
program will secure the future of research and treatment for bleeding and
clotting disorders."
The 2006 recipients of the NHF Clinical Fellowship Program grants are:
-- Jordan Shavit, M.D., Ph.D., University of Michigan, Ann Arbor - Dr.
Shavit earned a B.S., with Honors and High Distinction, in cellular
and molecular biology from the University of Michigan, Ann Arbor in
1992, and M.D. and Ph.D. from Northwestern University in 2000. His
training continued at the University of Michigan, Ann Arbor, where he
served as a House Officer.
-- Michael Callaghan, M.D., Children's Hospital of Michigan - Dr.
Callaghan earned his B.S. from Oakland University in 1997, and his
M.D. from Wayne State University in 2003. He completed a pediatric
residency program at the Children's Hospital of Michigan in 2005, and
continued as a pediatric hematology/oncology fellow until the present.
"We're proud to have a role in supporting these outstanding clinicians
as part of our ongoing commitment to the hemophilia community," said Peter
O'Malley, vice president of national accounts and advocacy, Baxter's
BioScience business in North America. "Specialized physicians who can
provide comprehensive care and continue to advance the treatment of
bleeding disorders are essential to the future of patient care."
About the NHF Clinical Fellowship Program
The NHF Clinical Fellowship program offers tuition reimbursement,
medical school loan assistance and hands-on training in clinical care for
bleeding disorders, as well as clinical research projects, at leading
hemophilia treatment centers across the country. Fellows learn the latest
diagnostic and therapeutic advances, standard practices and procedures for
clinical research, and the skills and knowledge required to provide
comprehensive care.
Graduates of the NHF Clinical Fellowship Program will lead research
efforts into bleeding and clotting disorders, work with legislators to
shape national healthcare policy, and train and support their peers in
providing better care to the bleeding disorders community. Through 2006, 13
clinicians have been selected as fellows by an independent panel since the
program's inception in 2003. Baxter's expanded sponsorship of the program
will support two fellows each year through 2008.
To be eligible for grants, institutions must be pre-approved by NHF as
hemophilia/thrombophilia treatment centers, with qualified clinical and
research faculty committed to the development of fellows. Candidates for
fellowship grants must have a medical degree, pre-fellowship clinical
training and an interest in bleeding or clotting disorders.
Additional program information and application materials can be found
on the NHF Web site at http://www.hemophilia.org .
About the National Hemophilia Foundation
The National Hemophilia Foundation is dedicated to finding better
treatments and cures for bleeding and clotting disorders and to preventing
the complications of these disorders through education, advocacy and
research.
Established in 1948, the National Hemophilia Foundation is a nonprofit
501(c)3 organization with chapters throughout the country. Its programs and
initiatives are made possible through the generosity of individuals,
corporations and foundations as well as through a cooperative agreement
with the Centers for Disease Control and Prevention (CDC).
About Baxter
Baxter Healthcare Corporation is a subsidiary of Baxter International
Inc. Baxter International Inc. (NYSE: BAX), through its subsidiaries,
assists healthcare professionals and their patients with the treatment of
complex medical conditions, including cancer, hemophilia, immune disorders,
kidney disease and trauma. The company applies its expertise in medical
devices, pharmaceuticals and biotechnology to make a meaningful difference
in patients' lives.
| |
SOURCE Baxter International Inc.
 back to top
Related links:
http://www.hemophilia.org
http://www.baxter.com
CONTACT:
John Indence of National Hemophilia
Foundation, +1-212-328-3763; or, Media, Deborah Spak,
+1-847-948-2349, Investors, Mary Kay Ladone, +1-847-948-3371, or
Clare Trachtman, +1-847-948-3085, all of Baxter International
Inc.
| |
|
